Görkem Türkkan

Görkem Türkkan

Auto-generated profile, based on publicly available information

Görkem Türkkan

Mugla Sitki Kocman Univ, Dept Radiat Oncol, Fac Med, Mugla, Turkey

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
GTGörkem Türkkan
Görkem Türkkan
YWYves Willems
Yves Willems
LHLizza E.L. Hendriks
Lizza E.L. Hendriks
RMRémy Mostard
Rémy Mostard
LCLennart Conemans
Lennart Conemans
DRDirk De Ruysscher
Dirk De Ruysscher

1 January 2017 in Archives of Medical Science
Verified
Journal Article
Closed access
ETEbru Tastekin
Ebru Tastekin
VCVuslat Yurut Caloglu
Vuslat Yurut Caloglu
NDNilufer Kilic Durankus
Nilufer Kilic Durankus
NSNecdet Sut
Necdet Sut
GTGorkem Turkkan
Gorkem Turkkan
MCMurat Caloglu
Murat Caloglu
Introduction : Among head and neck cancers, those of the oral cavity and oropharynx are the second most prevalent following the larynx. This study aimed to research immunohistochemical expression of survivin, HPV positivity and microvessel density in tumors and their relationships with...

20 September 2018 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
GTGorkem Turkkan
Gorkem Turkkan
OAOzgur Agdogan
Ozgur Agdogan
MSMert Saynak
Mert Saynak
AUArzu Calik Uygun
Arzu Calik Uygun
FUFunda Ustun
Funda Ustun

16 August 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
GTGorkem Turkkan
Gorkem Turkkan
NBNazli Bilici
Nazli Bilici
HSHuseyin Sertel
Huseyin Sertel
YKYavuz Keskus
Yavuz Keskus
SASercan Alkaya
Sercan Alkaya
MFMerdan Fayda
Merdan Fayda
Purpose: To report our initial experience with 1.5 T magnetic resonance imaging (MRI) linear accelerator (LINAC) in prostate cancer radiotherapy in terms of its use in a radiation oncology clinic.Methods: The medical records of 14 prostate cancer patients treated with MRI-guided radiotherapy were retrospectively evaluated. The fraction time, adapt-to-position (ATP):adapt-to-shape (ATS) usage rate, machine-associated treatment interruption rate, median gamma pass rate, the percentage of planning target volume receiving at least 95% of the prescription dose coverage value of each ATS fraction, the effect of the learning curve on the fraction time and radiation-related acute gastrointestinal and genitourinary toxicities were evaluated.Results: Fourteen patients have completed their treatment receiving a total of 375 fractions. Six patients (42%) were treated with the moderately hypofractionated regimen, five patients (36%) with conventionally fractionated, and three patients (22%) with the ultra-hypofractionated radiotherapy regimens. The ATP : ATS usage ratio was 3:372. The median fraction time was 46 min (range, 24-81 min). For the 3%/3 mm criterion, median gamma pass rate was 99.4% (range, 94.6–100%). Machine-related treatment interruptions were observed in 11 (2.9%) of 375 fractions, but this interruption rate decreased from 4.1% to 0.8%, after an upgrade. Three patients (22%) had gastrointestinal and five patients (36%) had genitourinary toxicity. No ≥grade 3 toxicity was observed.Conclusion: 1.5 T MRI-LINAC device could be used as a conventional LINAC device, when the conditions of the radiotherapy center are appropriate. MRI-guided prostate radiotherapy is safe and feasible, and high-quality studies with a larger number of patients and long-term results are needed to better evaluate this new technology.

10 November 2019 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
GTGorkem Turkkan
Gorkem Turkkan
CDCaner Dogan
Caner Dogan
BTBurak Tek
Burak Tek
Introduction: Bicalutamide is widely used in the treatment of prostate cancer. Among its side effects, central nervous system disorders are relatively rare, and the information about bicalutamide-associated hallucinations is limited. Case report: We report an uncommon case of a patient with metastatic prostate cancer, who had hallucinations due to the use of bicalutamide. Management and outcome: The patient accepted to receive only hormonal therapy (bicalutamide and leuprolide acetate). But he developed hallucinations due to bicalutamide use. His hallucinations disappeared after discontinuation of bicalutamide. A good response was obtained with the use of luteinizing hormone-releasing hormone agonist monotherapy. Discussion: The pathophysiology of bicalutamide-induced hallucinations is unclear. We hypothesize that antiandrogens can indirectly cause hallucinations through changes in plasma testosterone and cerebral reelin expression. Additionally, luteinizing hormone-releasing hormone agonist monotherapy is a good option in metastatic prostate cancer patients who have intolerable side effects due to the use of antiandrogens.